Fennec Pharmaceuticals Inc.
FRX.TO
Get informed when a big investor buys or sells
+ FollowMarket Cap$516.19M
Close$
Share Statistics
| Market cap | $516.19 Million |
|---|---|
| Enterprise Value | $478.13 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.34 |
| Beta | 1.07 |
| Outstanding Shares | 34,545,000 |
Return
| Return on Equity | -8.69% |
|---|---|
| Return on Assets | -4.87% |
| Return on Invested Capital | -2.70% |
Valuation & Multiples
| P/E Ratio | -82.38 |
|---|---|
| PEG | 50.67 |
| Price to Sales | 14.86 |
| Price to Book Ratio | 14.86 |
| Enterprise Value to Revenue | 8.04 |
| Enterprise Value to EBIT | -279.55 |
| Enterprise Value to Net Income | -130 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$0.03
Average shareholder expectationRevenue Estimate
$23.02 M
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$0.13
Average shareholder expectationRevenue Estimate
$26.92 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Fennec Pharmaceuticals Inc
35 employees
CEO: Rostislav Raykov Fennec Pharmaceuticals Inc., a biopharmaceutical firm established in 1996, operates from its base in Research Triangle Park, North Carolina. The company's lead investigational compound, PEDMARK, is a sodium thiosulfate formulation curren...